RUA Life Sciences, through its operating companies, is the rights holder to the novel bio-compatible polymer, Elast-Eon, provides third-party medical device development and manufacturing services and is internally developing Elast-Eon based medical devices to treat cardiovascular conditions. Financially, the company combines established recurring revenue streams with significant upside potential from its pipeline products. We believe the structure and financial opportunities RUA is targeting mak ....
14 Dec 2020
Cenkos: RUA Life Sciences Plc -- Targeting cardiovascular disease
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: RUA Life Sciences Plc -- Targeting cardiovascular disease
RUA Life Sciences Plc (RUA:LON) | 9.2 0 0.0% | Mkt Cap: 5.68m
- Published:
14 Dec 2020 -
Author:
Chris Donnellan -
Pages:
46
RUA Life Sciences, through its operating companies, is the rights holder to the novel bio-compatible polymer, Elast-Eon, provides third-party medical device development and manufacturing services and is internally developing Elast-Eon based medical devices to treat cardiovascular conditions. Financially, the company combines established recurring revenue streams with significant upside potential from its pipeline products. We believe the structure and financial opportunities RUA is targeting mak ....